|Back to Search Results|
Professor of Neurology
Professor of Pharmacology & Physiology (Secondary)
Office Phone: 202-741-2710
- BA, Case Western Reserve University, 1981
- MD, Case Western Reserve University, 1985
Dr. Kaminski is an internationally recognized expert in the care of patients with myasthenia gravis. He is part of the executive committee of the NIH-funded MGTX study which is designed to evaluate the efficacy of thymectomy for myasthenia gravis. His laboratory demonstrated efficacy of complement inhibitors for myasthenia gravis in preclinical trials and now works to develop second generation complement inhibitors. Along with collaborators at GWU and across the nation, he is working to identify biomarkers that may guide future clinical trials in myasthenia gravis. He continues to study the basic biology of extraocular muscle, which he has done for 20 years.
Diplomate, American Board of Psychiatry & Neurology (Neurology) Member, American Neurological Association (elected to membership) American Academy of Neurology Association of University Professors of Neurology (President 2012-14) Association of Experimental NeuroTherapeutics Myasthenia Gravis Foundation of America (past Chair Medical Scientific Advisory Board).
View publications by this faculty member from January 1, 2013 - present
Kusner LL, Halperin JA, Kaminski HJ. Cell surface complement regulators moderate experimental myasthenia gravis pathology. Muscle Nerve (accepted).
Minisman G, Bhanushali M, Conwit R, Wolfe G, Aban I, Kaminski HJ, Cutter G. Implementing clinical trials on an international platform: Challenges and perspectives J Neurol Sci 2012;313:1-6.
Zhou Y, Liu D, Kaminski HJ. Pitx2 regulates myosin heavy chain isoform expression and multi-innervation in extraocular muscle. J Physiol 2011;589:4601-14.
Kusner LL, Young A, Tjoe S, Leahy P, Kaminski HJ. Perimyseal fibroblasts of extraocular muscle are as unique as the muscle fibers. Invest Ophthalmol Vis Sci 2010;51:192-200.
Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol 2010;68:797-805.
Soltys J, Kusner LL, Young A, Richmonds C, Hatala D, Gong B, Shanmugavel V, Kaminski HJ. Novel Complement Inhibitor (rEV576) limits severity of experimentally acquired myasthenia gravis. Ann Neurol 2009;65:67-75.
Additional publications published before January 1, 2013 may be available within Himmelfarb Library's database.